Jody Casey Joins NAPA Anesthesia as Chief Growth Officer

North American Partners in Anesthesia (NAPA), the nation's leading single-specialty anesthesia management company, has appointed Jody Casey as Chief Growth Officer. In this role, Casey will focus on expanding relationships with existing partners while uncovering new business opportunities, aligning go-to-market efforts across sales and marketing, and advancing growth. https://mma.prnewswire.com/media/2839738/Jody_Casey_Chief_Growth_Officer.jpg Casey brings 25 years of leading […]

Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf GlobeNewswire December 08, 2025 PHILADELPHIA, Dec. 08, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

(NASDAQ:AUTL), Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) observed, consistent with obe-cel's adult safety profile FELIX study data analyses highlight product cell phenotype and level of CAR T

Dotz Nano to Present at the Small Cap Growth Virtual Investor Conference December 9th

(AUST:DTZ.AX),(Other OTC:DTZZF),(Other OTC:DTZNY), SYDNEY, Dec. 08, 2025 (GLOBE NEWSWIRE) — Dotz Nano Limited (ASX: DTZ, OTC: DTZZF/DTZNY, “Dotz” or “Company”), a leading developer of innovative climate and industrial nanotechnologies, today announced that Sharon Malka, Chief Executive Officer, will present at the Small Cap Growth Virtual Investor Conference on Tuesday, December 9, 2025 at 11:30 am

Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th

(TSX-V:TELO),(Other OTC:TDSGF), TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF), based in Toronto, a leader in diagnostic and prognostic innovation through its proprietary multi-factor telomere analytics platform, today announced that Guido Baechler, Executive Chairman, will present live at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com, on

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025

Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025 GlobeNewswire December 08, 2025 Obe-cel demonstrates high remission rates in pediatric patients with high-risk r/r B-ALL with overall response rate (ORR) of 95.5%; low rates of high-grade cytokine release syndrome

Dotz Nano to Present at the Small Cap Growth Virtual Investor Conference December 9th

Dotz Nano to Present at the Small Cap Growth Virtual Investor Conference December 9th Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com GlobeNewswire December 08, 2025 SYDNEY, Dec. 08, 2025 (GLOBE NEWSWIRE) — Dotz Nano Limited (ASX: DTZ, OTC: DTZZF/DTZNY, “Dotz” or “Company”), a leading developer

Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th

Telo Genomics Corp to Present at the Small Cap Growth Virtual Investor Conference December 9th Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com GlobeNewswire December 08, 2025 TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) — Telo Genomics Corp. (TSXV: TELO, OTCQB: TDSGF), based in Toronto, a leader

Agiloft Launches Enterprise-Grade Obligation Management, Pioneering the AI-Native Era of Contract Lifecycle Management

Enterprises gain real-time visibility and control over post-signature obligations, helping reduce risk, enforce compliance, and accelerate business outcomes, turning contract data into operational intelligence Agiloft, the global leader in data-first contract lifecycle management (CLM), today announced the release of its AI-driven Obligation Managementsolution, a suite of breakthrough capabilities that empowers enterprises to transform contracts into

GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program

Collaboration with Science Tokyo spinout underscores GlycoNex's integrated antibody development and manufacturing capabilities in support of first-in-class immunotherapies GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, today announced that it has entered into a CDMO service agreement with the Institute of Science

Scroll to Top